<DOC>
	<DOCNO>NCT02806362</DOCNO>
	<brief_summary>The purpose multicenter , single-arm , combination-drug study , include 12 week treatment 24 week follow-up , evaluate safety , efficacy pharmacokinetics ombitasvir/paritaprevir/ritonavir Japanese adult infect HCV GT1b , treatment-na√Øve treatment-experienced IFN-based regimen ESRD HD .</brief_summary>
	<brief_title>Study Ombitasvir/Paritaprevir/Ritonavir Japanese Adults With Genotype 1b Chronic Hepatitis C Virus ( HCV ) Infection With End Stage Renal Disease ( ESRD ) Hemodialysis ( HD )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Hepatitis C Virus ( HCV ) Ribonucleic acid ( RNA ) great 10,000 IU/mL Screening Chronic HCV , Genotype ( GT ) 1b infection Treatmentnaive treatmentexperienced interferon ( IFN ) contain regimen ( IFN pegylatedIFN without ribavirin ) . A fibrosis assessment test result equivalent Metavir F0F2 . Presence Y93H variant Screening Positive test result Hepatitis B surface antigen ( HBsAg ) antiHuman immunodeficiency virus antibody ( HIV Ab ) Significant liver disease cause chronic HCV infection On peritoneal dialysis On hemodialysis 15 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-cirrhotic</keyword>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>moderate fibrosis</keyword>
	<keyword>Chronic Hepatitis C Virus ( HCV )</keyword>
	<keyword>Chronic Hepatitis C Genotype 1b</keyword>
</DOC>